홈 > 시장보고서 > 의료기기 > 체외진단

시장보고서

상품코드

1605803

세계의 유방암 액체 생검 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 순환 바이오마커별, 용도별, 지역별 - 시장 예측(2025-2034년)

Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report: By Circulating Biomarkers, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast (2025-2034)

발행일: 2024년 11월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 116 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 유방암 액체 생검 세계 시장 규모는 2034년까지 27억 3,102만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

유방암 액체생검 시장은 전 세계 유방암 유병률 증가와 비침습적 진단 도구에 대한 수요 증가로 인해 크게 성장하고 있습니다. 액체 생검은 혈액 샘플에서 순환 종양 DNA(ctDNA)와 순환 종양 세포(CTC)를 분석합니다. 기존 조직 생검에 비해 환자의 불편함을 줄이고 치료 효과를 실시간으로 모니터링할 수 있는 등 몇 가지 장점이 있습니다. 분자생물학 및 유전체학의 발전으로 액체생검 검사가 개선되어 유방암을 조기에 발견하고 더 정확하게 치료할 수 있게 되어 시장 성장을 더욱 촉진하고 있습니다.

암 조기 발견의 이점에 대한 의료 전문가와 환자의 인식이 높아지면서 액체 생검 솔루션에 대한 수요가 증가하고 있습니다. 암 검진을 장려하는 정부의 이니셔티브와 연구 보조금도 시장 성장을 가속하는 데 중요한 역할을 하고 있습니다. 또한, 개인 맞춤형 의료로의 전환으로 표적치료에 대한 관심이 높아지면서 액체 생검은 환자별 유전자 프로파일을 기반으로 환자 개개인에게 맞춤화된 치료를 위한 필수적인 도구가 되고 있습니다.

대형 생명공학 기업과 제약회사의 존재와 활발한 연구개발 활동은 이 분야의 기술 혁신을 더욱 자극하고 있습니다. 의료 환경이 발전하고 액체 생검 기술을 채택하는 의료 기관이 증가함에 따라 액체 생검은 유방암의 진단과 관리를 개선하고 환자의 결과를 개선합니다. 위의 모든 요인은 유방암 액체 생검 시장의 성장을 가속할 것입니다.

유방암 액체 생검 시장 보고서 하이라이트

순환 바이오마커를 기준으로 2024년 순환 무세포 DNA(cfDNA) 부문은 민감도 향상으로 인해 유방암 액체 생검 시장에서 가장 큰 매출 점유율을 차지할 것으로 예상됩니다.

조기 암 진단의 중요성에 대한 인식이 높아짐에 따라 조기 발견/검진 분야는 예측 기간 동안 가장 높은 CAGR을 나타낼 것으로 예상됩니다.

2024년 북미가 유방암 액체생검 시장에서 가장 큰 점유율을 차지할 것으로 예상되는데, 이는 북미 전체에서 혁신적인 진단 기술 채택률이 높기 때문으로 분석됩니다.

아시아태평양 시장은 이 지역 전체에서 유방암 유병률이 증가함에 따라 예측 기간 동안 가장 높은 CAGR을 나타낼 것으로 예상됩니다.

세계 주요 시장 진출 기업으로는 Biocept, Inc. Laboratories, QIAGEN, QIAGEN, Sysmex Corporation, The Menarini Group, Thermo Fisher Scientific, Inc. 등이 있습니다.

주요 조사 결과
서론
- 유방암 액체생검 시장 평가 : 지역별, 2020년-2034년
북미
- 북미 : 순환 바이오마커별, 2020년-2034년
- 북미 : 용도별, 2020년-2034년
- 미국
- 캐나다
유럽
- 유럽 : 순환 바이오마커별, 2020년-2034년
- 유럽 : 용도별, 2020년-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
아시아태평양
- 아시아태평양 : 순환 바이오마커별, 2020년-2034년
- 아시아태평양 : 용도별, 2020년-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 중동 및 아프리카 : 순환 바이오마커별, 2020년-2034년
- 중동 및 아프리카 : 용도별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
라틴아메리카
- 라틴아메리카 : 순환 바이오마커별, 2020년-2034년
- 라틴아메리카 : 용도별, 2020년-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카

제8장 경쟁 구도

확대와 인수 분석
- 확대
- 인수
제휴/협업/합의/공개

제9장 기업 개요

The Menarini Group
NeoGenomics Laboratories
F. Hoffmann-La Roche Ltd.
Myriad Genetics, Inc.
Thermo Fisher Scientific, Inc.
QIAGEN
Biocept, Inc.
Sysmex Corporation
Fluxion Biosciences, Inc.
Epic Sciences, Inc.

LSH 24.12.19

The global breast cancer liquid biopsy market size is expected to reach USD 2,731.02 million by 2034, according to a new study by Polaris Market Research. The report "Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report - By Circulating Biomarkers [Circulating Tumor Cells (CTCs), Circulating Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers], Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The breast cancer liquid biopsy market is experiencing significant growth due to the increasing prevalence of breast cancer globally and the rising demand for noninvasive diagnostic tools. Liquid biopsy analyzes circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood samples. It offers several advantages over traditional tissue biopsies, including reduced patient discomfort and the ability to monitor treatment response in real time. Advancements in molecular biology and genomics have improved liquid biopsy tests, enabling earlier detection and more precise treatment of breast cancer, further boosting market growth.

The rising awareness among healthcare professionals and patients regarding the benefits of early cancer detection is driving demand for liquid biopsy solutions. Government initiatives promoting cancer screening and research funding also play a crucial role in fostering market growth. In addition, the shift toward personalized medicine is leading to a greater emphasis on targeted therapies, making liquid biopsies an essential tool for tailoring treatments to individual patients based on their unique genetic profiles.

The presence of major biotechnology and pharmaceutical companies, coupled with robust research and development activities, is further stimulating innovation in this sector. As the healthcare landscape evolves and more providers adopt liquid biopsy technology, it improves breast cancer diagnosis and management while enhancing patient outcomes. All these factors mentioned above drive the breast cancer liquid biopsy market growth.

Breast Cancer Liquid Biopsy Market Report Highlights

Based on circulating biomarkers, in 2024, the circulating cell-free DNA (cfDNA) segment accounted for the largest revenue share in the breast cancer liquid biopsy market due to its enhanced sensitivity.

The early detection/screening segment, by application, is expected to register the highest CAGR during the forecast period due to the increasing awareness of the importance of early cancer diagnosis.

In 2024, North America accounted for the largest share of the breast cancer liquid biopsy market due to high adoption rates of innovative diagnostic technologies across the region.

The Asia Pacific market is expected to register the highest CAGR during the forecast period due to an increasing prevalence of breast cancer across the region.

A few global key market players are Biocept, Inc.; Epic Sciences, Inc.; F. Hoffmann - La Roche Ltd.; Fluxion Biosciences, Inc.; Myriad Genetics, Inc.; NeoGenomics Laboratories; QIAGEN; Sysmex Corporation; The Menarini Group; and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the breast cancer liquid biopsy market report on the basis of circulating biomarkers, application, and region:

By Circulating Biomarkers Outlook (Revenue - USD Million, 2020-2034)

Circulating Tumor Cells (CTCs)
Circulating Cell-Free DNA (cfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers

By Application Outlook (Revenue - USD Million, 2020-2034)

Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Breast Cancer Liquid Biopsy Market Insights

4.1. Breast Cancer Liquid Biopsy Market - Market Snapshot
4.2. Breast Cancer Liquid Biopsy Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Technological Advancements are Driving the Market Growth
  - 4.2.1.2. Rising Prevalence of Breast Cancer are Driving the Market Growth
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Development Costs
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Breast Cancer Liquid Biopsy Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
5.3. Circulating Tumor Cells (CTCs)
- 5.3.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Tumor Cells (CTCs), by Region, 2020-2034 (USD Million)
5.4. Circulating Cell-free DNA (cfDNA)
- 5.4.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Cell-free DNA (cfDNA), by Region, 2020-2034 (USD Million)
5.5. Extracellular Vesicles (EVs)
- 5.5.1. Global Breast Cancer Liquid Biopsy Market, by Extracellular Vesicles (EVs), by Region, 2020-2034 (USD Million)
5.6. Other Circulating Biomarkers
- 5.6.1. Global Breast Cancer Liquid Biopsy Market, by Other Circulating Biomarkers, by Region, 2020-2034 (USD Million)

6. Global Breast Cancer Liquid Biopsy Market, by Application

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
6.3. Early Detection/Screening
- 6.3.1. Global Breast Cancer Liquid Biopsy Market, by Early Detection/Screening, by Region, 2020-2034 (USD Million)
6.4. Diagnosis
- 6.4.1. Global Breast Cancer Liquid Biopsy Market, by Diagnosis, by Region, 2020-2034 (USD Million)
6.5. Monitoring
- 6.5.1. Global Breast Cancer Liquid Biopsy Market, by Monitoring, by Region, 2020-2034 (USD Million)

7. Global Breast Cancer Liquid Biopsy Market, by Geography

7.1. Key Findings
7.2. Introduction
- 7.2.1. Breast Cancer Liquid Biopsy Market Assessment, By Geography, 2020-2034 (USD Million)
7.3. Breast Cancer Liquid Biopsy Market - North America
- 7.3.1. North America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.3.2. North America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.3.3. Breast Cancer Liquid Biopsy Market - U.S.
  - 7.3.3.1. U.S.: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.3.3.2. U.S.: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.3.4. Breast Cancer Liquid Biopsy Market - Canada
  - 7.3.4.1. Canada: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.3.4.2. Canada: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
7.4. Breast Cancer Liquid Biopsy Market - Europe
- 7.4.1. Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.4.2. Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.3. Breast Cancer Liquid Biopsy Market - UK
  - 7.4.3.1. UK: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.3.2. UK: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.4. Breast Cancer Liquid Biopsy Market - France
  - 7.4.4.1. France: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.4.2. France: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.5. Breast Cancer Liquid Biopsy Market - Germany
  - 7.4.5.1. Germany: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.5.2. Germany: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.6. Breast Cancer Liquid Biopsy Market - Italy
  - 7.4.6.1. Italy: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.6.2. Italy: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.7. Breast Cancer Liquid Biopsy Market - Spain
  - 7.4.7.1. Spain: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.7.2. Spain: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.8. Breast Cancer Liquid Biopsy Market - Netherlands
  - 7.4.8.1. Netherlands: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.8.2. Netherlands: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.9. Breast Cancer Liquid Biopsy Market - Russia
  - 7.4.9.1. Russia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.9.2. Russia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.10. Breast Cancer Liquid Biopsy Market - Rest of Europe
  - 7.4.10.1. Rest of Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.10.2. Rest of Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
7.5. Breast Cancer Liquid Biopsy Market - Asia Pacific
- 7.5.1. Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.5.2. Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.3. Breast Cancer Liquid Biopsy Market - China
  - 7.5.3.1. China: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.3.2. China: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.4. Breast Cancer Liquid Biopsy Market - India
  - 7.5.4.1. India: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.4.2. India: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.5. Breast Cancer Liquid Biopsy Market - Malaysia
  - 7.5.5.1. Malaysia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.5.2. Malaysia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.6. Breast Cancer Liquid Biopsy Market - Japan
  - 7.5.6.1. Japan: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.6.2. Japan: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.7. Breast Cancer Liquid Biopsy Market - Indonesia
  - 7.5.7.1. Indonesia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.7.2. Indonesia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.8. Breast Cancer Liquid Biopsy Market - South Korea
  - 7.5.8.1. South Korea: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.8.2. South Korea: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.9. Breast Cancer Liquid Biopsy Market - Australia
  - 7.5.9.1. Australia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.9.2. Australia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.10. Breast Cancer Liquid Biopsy Market - Rest of Asia Pacific
  - 7.5.10.1. Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.10.2. Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
7.6. Breast Cancer Liquid Biopsy Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.6.2. Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.3. Breast Cancer Liquid Biopsy Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.3.2. Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.4. Breast Cancer Liquid Biopsy Market - UAE
  - 7.6.4.1. UAE: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.4.2. UAE: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.5. Breast Cancer Liquid Biopsy Market - Israel
  - 7.6.5.1. Israel: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.5.2. Israel: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.6. Breast Cancer Liquid Biopsy Market - South Africa
  - 7.6.6.1. South Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.6.2. South Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.7. Breast Cancer Liquid Biopsy Market - Rest of Middle East & Africa
  - 7.6.7.1. Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.7.2. Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
7.7. Breast Cancer Liquid Biopsy Market - Latin America
- 7.7.1. Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.7.2. Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.7.3. Breast Cancer Liquid Biopsy Market - Mexico
  - 7.7.3.1. Mexico: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.7.3.2. Mexico: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.7.4. Breast Cancer Liquid Biopsy Market - Brazil
  - 7.7.4.1. Brazil: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.7.4.2. Brazil: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.7.5. Breast Cancer Liquid Biopsy Market - Argentina
  - 7.7.5.1. Argentina: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.7.5.2. Argentina: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.7.6. Breast Cancer Liquid Biopsy Market - Rest of Latin America
  - 7.7.6.1. Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.7.6.2. Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. The Menarini Group
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. NeoGenomics Laboratories
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. F. Hoffmann - La Roche Ltd.
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Myriad Genetics, Inc.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Thermo Fisher Scientific, Inc.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. QIAGEN
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Biocept, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Sysmex Corporation
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Fluxion Biosciences, Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Epic Sciences, Inc.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,250

￦ 6,149,000

PDF (Multi User License)

PDF 보고서를 동일 기업 20명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,250

￦ 7,596,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,250

￦ 9,043,000

※ 부가세 별도

세계의 유방암 액체 생검 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 순환 바이오마커별, 용도별, 지역별 - 시장 예측(2025-2034년)

Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report: By Circulating Biomarkers, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast (2025-2034)

유방암 액체 생검 시장 보고서 하이라이트

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 유방암 액체생검 시장 인사이트

제5장 세계의 유방암 액체생검 시장 : 순환 바이오마커별

제6장 세계의 유방암 액체생검 시장 : 용도별

제7장 세계의 유방암 액체생검 시장 : 지역별